Segulah Medical Acceleration

Protembis GmbH, founded in 2017 and based in Aachen, Germany, specializes in the manufacture of surgical equipment aimed at enhancing the safety of transcatheter aortic valve replacement (TAVR) procedures. The company has developed the ProtEmbo System, an intra-aortic filter device designed to mitigate the risk of cerebrovascular events during TAVR by deflecting embolic material away from the cerebral circulation. This innovation addresses a significant complication associated with TAVR, which has become a preferred treatment for patients with valvular heart disease, particularly as the procedure is increasingly performed on younger and lower-risk individuals. By minimizing the risk of brain injury, Protembis aims to improve patient outcomes and reduce healthcare costs related to surgical complications.

Collective Minds Radiology is a cloud-based healthcare company that provides a digital platform for radiologists to collaborate on diagnosing imaging findings. The platform facilitates the sharing of cases among experts and hospitals, allowing for clinical audits that help monitor quality and improve diagnostic accuracy. In addition to fostering collaboration, the company offers clinical consultation, research, and educational services, building a network that combines human expertise with artificial intelligence. This innovative approach aims to enhance the capabilities of healthcare professionals and create a comprehensive reference library for improved analysis.

Navinci Diagnostics AB is a Swedish company specializing in biomolecular analysis for cancer and prenatal diagnostics. Based in Uppsala, it develops proprietary technology aimed at detecting and quantifying proteins, their interactions, and modifications in various biological samples, including tissue, cells, and blood. The company offers a range of products, including universal kits suitable for cultured cells and fresh-frozen or FFPE samples, as well as target-specific kits that are pre-optimized for specific variables. In addition to its product offerings, Navinci Diagnostics provides in-house immunostaining and custom assay services, enhancing its capabilities in the field of diagnostics.

Signifier Medical Technologies Limited specializes in manufacturing and marketing equipment aimed at assisting with sleep disorders, particularly sleep apnea and snoring. Founded in 2015 and headquartered in London, the company operates under the Snoozeal brand, offering innovative solutions that address the root causes of sleep-disordered breathing. Its flagship product utilizes a flexible silicone device that employs low-intensity electrical pulses to train tongue muscles, aiming to prevent snoring and alleviate mild sleep apnea symptoms. The company was previously known as Snoozeal Limited until it rebranded in May 2019. Signifier Medical Technologies is committed to enhancing the quality of life and sleep for its customers by providing alternatives to conventional treatments that often focus solely on symptom management rather than addressing underlying issues.

Allurion Technologies, Inc. is a medical device company based in Natick, Massachusetts, founded in 2009. It specializes in developing innovative solutions for weight loss, particularly through its flagship product, the Allurion Balloon. This unique intragastric balloon is designed to be swallowed in capsule form, allowing for a non-surgical approach to obesity treatment. Once ingested, the balloon expands in the stomach, promoting a feeling of fullness to aid in weight loss. The company also offers the Allurion Program, which includes AI-powered remote monitoring, a behavior change program, and telehealth services to support patients throughout their weight loss journey. Allurion's approach aims to provide effective weight management without the need for surgery or endoscopy.

SAGA Diagnostics AB is a company specializing in molecular genetic tests and services aimed at enhancing cancer diagnostics and disease monitoring for healthcare providers, biopharmaceutical firms, and academic institutions. Founded in 2016 as a spin-out from a research group at Lund University, SAGA focuses on the analysis of circulating tumor DNA (ctDNA), a critical biomarker for cancer. The company offers a range of services, including gene mutation analysis, chromosome analysis, and non-invasive liquid biopsy testing, which allows for the ultrasensitive detection of actionable mutations. SAGA's proprietary technology supports oncologists and drug developers by enabling the stratification of patient groups and monitoring treatment responses, thereby facilitating more precise cancer medicine and improving patient outcomes. Based in Lund, Sweden, SAGA is driven by a team of experienced scientists and professionals dedicated to advancing cancer research and clinical diagnostics.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

CytaCoat is a private Swedish company headquartered in the Karolinska Institutet Science Park in Solna, established by researchers from the Karolinska Institute and the Royal Institute of Technology. The company focuses on developing an innovative antibacterial coating technology for medical devices aimed at preventing healthcare-associated infections. Their proprietary polymer surface demonstrates effectiveness against several problematic pathogenic bacteria, addressing a significant challenge in healthcare. CytaCoat’s technology is designed to be stable under varying pH and ionic conditions, minimizing the release of potentially toxic components and preventing bacterial colonization without relying on antibiotics, which can lead to resistance. The company operates a fully equipped laboratory for microbiology evaluations and technology optimization, and it has established collaborations with clinical partners at the Karolinska University Hospital. Additionally, CytaCoat works with consultants specializing in regulatory affairs, clinical research, patenting, and specialized analyses to advance their product towards commercial viability and licensing opportunities.

Vidya Health is the medical technology company based in London